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In the case of cancer, death is usually not due to the primary tumor itself but due to dissemination. Analysis of the
circulating tumor cells (CTCs), i.e., cells responsible for a formation of metastases, should provide information useful
for the management of cancer patients, fulfilling the objectives of predictive, preventive, and personalized medicine
(PPPM). Despite promising results, the decisions on stage of disease and how to guide the adjuvant treatment still
do not include results of CTC assessment. We want to describe two major reasons why the recent diagnostic value
of CTC analysis is not sufficient for clinical use. The first reason arises from the biological nature of the tumor itself
and the second reason is associated with an interdisciplinary status of CTC diagnostics in the sense that it is neither
a theme purely for pathologists nor for haemato-oncologists nor clinical biochemists. We anticipate that there are
at least three areas where CTCs can be useful for clinical practice. The first is monitoring of treatment efficacy of
cancer patients. The second is a molecular characterization of captured CTCs for targeted treatment, and the third is
a cultivation of captured CTCs for drug sensitivity testing. All of these approaches allow researchers recognize and
respond to changes of phenotype of cancer cells during disease progression and introduce PPPM into clinical practice.
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Introduction
In the case of cancer, death is usually not due to the pri-
mary tumor itself but due to dissemination, i.e., the for-
mation of distant metastases, that may develop years
after the removal of the primary tumor. Even though no
evidence of tumor spread may be seen at the time of the
primary diagnosis, as we can see in breast cancer, a rele-
vant number of axillary lymph node-negative breast cancer
patients also develop local or distant metastases [1,2]. Al-
though imaging has been, and still is, the gold standard for
prognosis estimation and disease monitoring, there are
emerging alternative approaches that could reveal micro-
metastases earlier and, combined with traditional methods,
could improve monitoring of the disease status [3]. Moni-
toring and analysis of the cells responsible for metastases
formation should give information useful for the treatment* Correspondence: martin.pesta@lfp.cuni.cz
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“liquid biopsy” [4].
The presence of detached tumor cells in peripheral
blood, similar to cells of the primary solid tumor, was
first recognized and described by Thomas R. Ashworth
in 1869 [5]. The intensive research in last 15 years has
brought progress in knowledge on how the tumor is
spread by tumor cells in the peripheral blood, lymph nodes,
or bone marrow and about the phenotype and genotype of
these cells. We are witnessing a paradoxical situation. This
deeper knowledge shows the complexity and nonuniformity
of the metastatic process, resulting in delays of the use of
circulating tumor cells (CTCs) in the clinical management
of oncological patients on the one hand, while on the other
hand, allowing individualization of treatment in the future.
The goal of this review is to summarize problematic
points that may postpone implementation of CTC as-
sessment in clinical practice, i.e., issues that are currently
being dealt with in relation to the clinical value of CTCs.
We also want to discuss in which areas of cancer man-
agement of patients there is the greatest benefit of CTC
examinations. For this, we have specifically focused on
CTC assessment in breast and colorectal cancer.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diagnostic value of CTC analysis is still not sufficient for
routine clinical use. The first reason arises from the
biological nature of the tumor itself, for example, intratu-
moral heterogeneity and its relation to the composition of
the population of cells detached into the lymphatic system
and blood stream. Understanding the mechanisms behind
the epithelial-mesenchymal transition (EMT) and the
transformation from cancer stem cells to differentiated
cells helps to reveal properties of subpopulation of CTCs.
The second reason is associated with an interdisciplinary
status of CTC diagnostics in the sense that it is neither a
theme purely for pathologists nor for haemato-oncologists
nor clinical biochemists. Despite whether the origin of
CTCs is in the primary tumor or its metastasis, i.e., in
solid tumor, the place of detection is the blood. Therefore,
this problematic issue is not in the scope of pathologists.
As the origin of CTCs is not in haematopoetic cells, it is
not a field of interest for haemato-oncologists. It is pos-
sible to say that this marker becomes a topic for biochem-
ists as a potential oncomarker. One of the consequences
of this interdisciplinary character of CTCs is also a
broad spectrum of detection techniques currently used
in research. There are methods similar to pathology meth-
odology which utilizes microscopy (HD-CTC assay tech-
nology licensed to Epic Sciences, San Diego, CA, USA) [6],
while the other techniques are similar to flow cytometry
(CellSearch system licensed to Veridex, Raritan, NJ, USA)
[7], or the methods are based on a combination of
immunomagnetic enrichment and molecular biology
approach (RT-PCR) [8]. However, we can also find the
creative methods such as photoacoustic flow cytometry
[9] or microfluidic platforms [10]. The broad spectrum of
methods associated with the detection of CTCs is based
on their various phenotypical properties, and so, it is diffi-
cult to compare data obtained by different techniques
[11]. This therefore results in a lack of large randomized
trials that would confirm or refute the benefits of patients’
management, based on decisions made by the determin-
ation of CTCs.
Definition of CTCs and metastatic phenotype of tumor
cells
The major challenge of the current research of CTCs is
to clearly define the phenotype of cells that are the source
of new tumor nests (metastasis). As such, this question is
tightly coupled with understanding carcinogenesis as a
whole. To date, the significance of the role of cancer
stem cell phenotypes in primary tumor growth and the
role of EMT in cancer progression is still not fully
understood [12-14].
Simply, a CTC is a tumor cell present in the peripheral
blood, as a general definition. However, presently, there is
no generally accepted agreement about CTC phenotypes—i.e., surface markers defining CTC. This is one of the
reasons that there are many approaches for detection of
CTCs. Most detection systems use markers of CTCs
epithelial cell adhesion molecule (EpCAM) and cyto-
keratins (intermediate filaments specific for epithelial
cells). EpCAM is expressed to various degrees by many
epithelial tumor cells and functions as a homotypic
calcium-independent cell adhesion molecule [15,16].
Cytokeratins are broadly expressed by epithelial tumor
cells, including both low (8, 18, and 19) and high-molecular
weight (1, 5, 10, and 14) cytokeratins [17]. Both EpCAM
and cytokeratins are detectable by immunofluorescence
techniques.
A CTC is identified by many methods as a nucleated
cell that is positive for EpCAM, is cytokeratin positive,
and is CD45 negative. This strategy targets tumor cells in
peripheral blood as cells having a nonhematopoetic pheno-
type with epithelial characteristics. On the basis of this
CTC definition, a lot of successful work has been done.
For example, it was found that the amount of CTCs differs
in various types of tumors, as was shown in the work of
Allard et al., Figure 1, [18]. In some groups of patients, it
was found that the number of CTCs detected is related to
prognosis [19-21]. The simplest approach, enumeration, is
based on the number of detected CTCs. The result (the
number of detected CTCs) strongly depends on detection
technique. It is necessary to mention that this approach
passes other properties and processes which are to current
knowledge associated with malignant potential as EMT or
cohesive and collective cell migration.
Despite many clinical studies that have confirmed the
prognostic potential of EpCAM positive CTCs, there is
evidence that cannot be ignored and that the cells re-
sponsible for formation of metastases can be those
which express stem cell properties and also express
some molecules typical for cells that have undergone
EMT [22,23]. Such cells do not necessarily express
EpCAM and may be missed by currently used detection
techniques [24,25]. Moreover, recent findings have
shown that CTCs are not a uniform population [26] and
it is apparent that not all of them have the same poten-
tial to form secondary tumors.
From a statistical point of view, it is not surprising that
an adverse outcome is predicted by a greater number
of CTCs detected in peripheral blood on the basis of
EpCAM+, CK+, and CD45- phenotype. Despite the fact
that the specific CTCs that are detected may not have
metastatic potential themselves, it can be expected that
the detection of a higher number of these CTCs predicts
an increase in those CTCs with metastatic potential.
Therefore, although we do not detect the right CTCs,
we probably obtain the correct result.
The majority of studies targeted for detection of CTC
CK+ and EpCAM+ phenotype and deal with breast and
Figure 1 CTC count in different metastatic cancer types; data adapted from [18]. The plot compares CTC counts enumerated by CellSearch
system (the number of CTCs in 7.5 ml of whole blood) from healthy donors (normals) and patients with nonmalignant diseases (benigns) with
CTC counts from patients with metastatic prostate, breast, lung, ovarian, colorectal, pancreatic, and other cancers.
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focused on CTC assessment in these tumor types.
CTCs as prognostic markers in breast cancer
Breast cancer is the most commonly diagnosed type of
cancer in women, and the risk of development of this
disease during life is one in nine [27]. Primary detection
and diagnosis is mainly based on imaging methods such
as ultrasound and mammography [28]. Breast cancer is a
highly heterogeneous disease, and the histopathological
classification includes some 20 major tumor types and
18 minor subtypes [29]. For the treatment, basic classifica-
tion is based on the assessment of expression of estrogen
receptors (ER), progesterone receptors (PgR), and HER2
status [30]. Imaging methods alone cannot provide infor-
mation about the definite tumor type [31], and the possi-
bility of monitoring of disease development is also limited,
especially by size of tumor mass.
The role of CTCs as prognostic markers has been re-
ported by many clinical studies, and several clinical trials
in both, primary and metastatic breast cancer [32-36], all
supporting a significant correlation between CTC amount,
progression-free survival (PFS), and overall survival (OS).
This correlation was recently confirmed by a meta-
analysis involving data of 1,944 patients from 17 European
centers, with the conclusion that CTC count is an inde-
pendent prognostic marker of PFS and OS [37].
Until recently, most of the large studies have been done
on a group of patients with metastatic breast cancer. Thisyear, results of the SUCCESS study, a large patient cohort
study focused on early breast cancer, were published. This
trial provides strong evidence for the prognostic relevance
of CTCs both before and after adjuvant chemotherapy
and supports the clinical potential of CTCs to assess the
individual risk of patients at the time of primary diagnosis
[38]. The prognostic role of CTC enumeration has been
shown to be dependent on the type of primary tumor and
is more pronounced in ER-positive and triple-negative
than in HER2-positive metastatic breast cancer [39].
CTCs as prognostic markers in colorectal cancer
Colorectal cancer (CRC) is another leading cause of cancer-
related death in developed countries [40]. Five year survival
rates are over 90% for stage I disease and are lower than
10% for patients in stage IV [41]. However, up to 25% of
the patients with localized disease subsequently develop
disease relapse and metastases [42]. Major effort is to
improve the survival rates for patients with metastatic
CRC. Targeted therapies, based on the use of monoclonal
antibodies directed against the epidermal growth-factor
receptor (EGFR) and vascular endothelial growth factor
(VEGF), have been shown as promising treatments [43].
The role of CTCs as prognostic markers for primary colo-
rectal cancer has been reported in many studies [44,45], that
generally concluded that the presence of CTC in peripheral
blood is a marker of poor disease-free survival in patients
with nonmetastastic CRC. Similarly, detection of CTCs in
peripheral blood of patients with resectable colorectal liver
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disease progression and poor survival. In multivariable
analyses, the detection of CTCs is an independent prog-
nostic factor [46].
Despite these promising results, the decisions on stage
of disease and how to guide the adjuvant treatment
(oncological guidelines) still do not include the results of
CTC assessment. It could be expected that the imple-
mentation to standards of care could be facilitated by a
standardized and automated system for CTC detection,
e.g., CellSearch, which currently holds a dominant pos-
ition in the field of CTC detection instruments.
The complexity of the CTC topic becomes apparent in
comparison with immediate integration of KRAS mutation
assessment into routine oncological clinical practice. The
analysis of the presence of KRAS mutations in tumor
tissue in patients treated with EGFR-tyrosine kinase in-
hibitors (TKIs) was conducted in works of Pao et al.
[47] and Massarelli et al. [48]. These studies suggested
an association between KRAS mutations and an absence
of response to EGFR-TKIs treatment. Since 2009, KRAS
mutational status has been recommended to guide the
therapy in oncological patients treated by EGFR-TKIs and
anti-EGFR monoclonal antibodies, according to KRAS
mutational status. This was the first genetic test to guide
the treatment of cancer [49-51].
CTCs in management of oncological patients
Nevertheless, there is still a question regarding the place
for CTC assessment in clinical oncology and if this place
exists at all. It remains to be determined whether an al-
ternative approach, which is easier and cheaper, could pro-
vide similar information. From our point of view, there are
at least three areas where CTCs can be useful for clinical
practice. First is the monitoring of treatment efficacy of
cancer patients. Second is the molecular characterization
of captured CTCs for targeted treatment, and third is
the cultivation of captured CTC for drug sensitivity
testing. All these assessments provide information about
the current status of the disease and allow a personalized
approach.
Monitoring of therapy
In clinical practice, imaging technologies such as com-
puted tomography (CT), positron emission tomography
(PET), and magnetic resonance imaging (MRI) and la-
boratory determination of tumor marker levels are well-
established methods for monitoring cancer patients and
determining the effect of treatment. However, using these
approaches, long periods are required to record reliable
information on the effect of the treatment, and during this
period, the patients can be exposed to potentially unneces-
sary therapy that may increase treatment-associated com-
plications, such as neutropenia, neuropathy, and alopecia.Monitoring of CTC level has an inherent potential to pro-
vide information on the effects of treatment. The level of
CTCs appears to respond more rapidly to the treatment,
in as little as a few weeks [52,53].
In 2006, Budd et al. did a direct comparison between
enumeration of CTCs and radiological imaging in meta-
static breast cancer patients for prediction of OS [54].
One hundred and thirty-eight metastatic breast cancer
patients had imaging studies done before and a median
of 10 weeks after the initiation of therapy. CTC counts
were determined 4 weeks after initiation of therapy. This
study showed for the first time that CTC enumeration is
a reliable and accurate way to monitor disease progres-
sion, offering an earlier and more reproducible monitor-
ing than standard anatomic imaging methods [54].
Liu et al. showed that five or more CTCs predict for
poorer PFS in patients with metastatic breast cancer and
demonstrated a strong correlation between CTC results
and radiographic disease progression monitoring in patients
receiving chemotherapy or endocrine therapy. Importantly,
correlation was applied to CTC results obtained at the time
of imaging before imaging and after imaging [55]. Similar
results to Liu et al’s study have also been published. For ex-
ample, a study by De Giorgi showed the possibility that the
number of detected CTCs, might be connected to the loci
of metastasis, and that a higher number of CTCs might
indicate bone metastasis [56,57].
In 2014, a study “Circulating Tumor Cells and Response
to Chemotherapy in Metastatic Breast Cancer: SWOG
S0500” concluded with a disappointing outcome. Despite
this study confirming the prognostic significance of CTCs
in patients with metastatic breast cancer receiving first-
line chemotherapy, for patients with persistently increased
CTCs after 21 days of first-line chemotherapy, early
switching to an alternate cytotoxic therapy was not ef-
fective in prolonging OS. For such patients, there is a
need for a more effective treatment than standard chemo-
therapy. It is obvious that monitoring of the effect of can-
cer treatment is particularly important when we can offer
to patients another effective treatment [58]. This result
showed that successful use of CTC in patients’ manage-
ment, especially in monitoring of therapy, is coupled with
the availability of alternative effective drugs and other lines
of treatment.
Molecular characterization of captured CTCs for decisions
about the treatment
Molecular characterization of CTCs at the DNA level
and assessments of expression at the RNA and protein
levels can provide information on the presence of thera-
peutic targets and also the presence of changes that are
predictors of ineffective therapy. For the patients and
their clinicians, the question of properly selected treatment
is absolutely crucial. As well as analysis of the tumor tissue
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the current molecular targets for treatment and predictors
of resistance. As it has been shown, the results from both
sources are not always consistent [59-61]. In the time
of progression and recurrence of disease, genotype and
phenotype are changing and re-evaluation of current
molecular targets is a strategy with clinically exploitable
potential.
Finding molecular targets and correctly defining target
groups of patients is important to pharmaceutical com-
panies; molecular characterization of CTCs may contrib-
ute to the development of novel anticancer drugs.
Molecular characterization of CTCs in breast cancer
In breast cancer, the presence of HER2/neu receptor on
the surface of CTCs could be useful molecular characteris-
tic. Knowledge of the HER2/neu receptor expression, not
only in tumor cells of the primary tumor but also in cells
released from it, CTCs, can help determine the correct
choice of treatment for patients with breast cancer. A
study conducted by Wülfing et al. showed that HER2-
positive CTCs indicated poor clinical outcome in stages
I to III breast cancer patients. In addition, Wülfing ob-
served in 12 (from 17) patients with HER2-positive CTCs,
the primary tumor was negative for HER2, as assessed
by immunohistochemical score and fluorescence in situ
hybridization [62]. Similarly, in another study, Munzone
et al. recorded 18% discordance between HER2-positive
CTCs and HER2 status of the primary tumor cells [60].
There is also evidence that HER2 status can change
during disease recurrence or progression in breast can-
cer patients. Fehm et al. provide HER2 status of CTCs
in patients with metastatic breast cancer and observed
HER2-positive CTCs in 32% and 49% (CellSearch assay
and AdnaTest BreastCancer, respectively) of patients with
HER2-negative primary tumors [63]. In our study on early
breast cancer patients as luminal A type, we also observed
a discrepancy between HER2 status of the primary tumor
cells and HER2-positive CTC (unpublished data).
Discrepancies between the molecular characteristics of
the primary tumor and CTCs are targets of interest in a
randomized phase II trial for patients with HER2-negative
primary breast cancer, who after completing (neo)adjuvant
chemotherapy and surgery, have detectable CTCs in their
peripheral blood. Nonmetastatic HER2-negative patients,
but with detectable CTCs by CellSearch after surgery in
their peripheral blood and HER2/neu-positive CTCs,
were randomized after neoadjuvant treatment to receive
adjuvant trastuzumab [64]a. The study is coordinated by
European Organisation for Research and Treatment of
Cancer, Network of Core Institutions, and the results
will be available in 2015.
At the time when metastatic disease is identified,
knowledge of HER2/neu status could help to optimizetreatment decisions. Since HER2 positivity could be ac-
quired during disease progression, assessment of the HER2
status in CTCs may be clinical important in patients whose
HER2 status was not determined in the primary tumor.
This is especially relevant in patients where tissue sampling
and direct analysis of metastatic tissue may be difficult to
obtain (due to its location). In a study by Fehm, a subgroup
of patients with initially negative or unknown HER2 status
can have HER2-positive CTCs at the time of development
of metastatic disease. Fehm observed that eight out of
21 breast cancer patients with detectable CTCs and with
negative or unknown primary tumor HER2 status exhib-
ited HER2 amplification [59].Molecular characterization of CTCs in colorectal cancer
Molecular characterization of CTC may prove to be use-
ful in the management of patients with metastatic CRC
by helping to predict treatment response to biological ther-
apy. In patients with metastatic CRC prior to administering
therapy that uses anti-EGFR monoclonal antibody, the
test of the presence of activating KRAS mutation is rec-
ommended. KRAS and BRAF mutations are currently
assessed in the primary tumor tissue. It was shown that
the mutation status of the primary tumor is not always
identical with metastases. Santini et al. [65] and Molinari
et al. [66] performed analysis of KRAS mutations from pri-
mary CRC and from visceral and lymph node metastasis,
finding a concordance of 96% and 92%, respectively.
Baldus et al. [67] observed a concordance rate between
primary tumor and visceral metastasis (90%), but not with
lymph nodes metastasis (31%). On the other hand, Tortola
et al. [68] found a significant discordance rate between
tumor and related bone marrow metastases.
It is not suppressing that not all patients with wild type
KRAS in the primary tumor are successfully treated with
anti-EGFR antibodies. In the case of doubts of KRAS
status in the primary tumor, tests of KRAS mutations
in metastatic tissue could be useful, but this can be lim-
ited by obtaining patients’ cancer tissues. To improve
patient selection, assessment of mutation status in CTCs
could possibly better represent the presence of mutations
in metastases, than the primary tumor. As shown in
the work by Yen et al., the detection sensitivity, specifi-
city, and accuracy of membrane-arrays for CTCs with
KRAS oncogene significantly correlate to KRAS mutations
in tumors (P < 0.0001) [69]. Other studies have shown
similar results, but it is necessary to mention that different
methods of CTC detection were used [70]. Sastre’s post
hoc analysis showed that CTC count and their KRAS
status were independent prognostic factors for outcomes in
patients with metastatic CRC treated with bevacizumab ±
chemotherapy [71]. Similarly, Kuboki’s study showed that
a high CTC count predicted reduced OS in patients with
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therapy as a third-line treatment [72].
These results suggest that the assessment of CTCs
might provide important predictive and prognostic infor-
mation for such patients and that the inclusion of KRAS
status of CTCs into other trials certainly makes sense.
However, the reasons of unsuccessful treatment are com-
plicated. The work of Gasch et al. points to considerable
intra- and interpatient heterogeneity of EGFR expression
and genetic alterations in EGFR, KRAS, and PIK3CA, thus
possibly explaining the variable response rates to EGFR in-
hibition in patients with CRC [73].
As well as CTC KRAS status determination, assessment
of other genes in captured CTC may improve prediction
of treatment response. Determining the expression of
genes of tumor cells involved in the metabolism of che-
motherapeutic agents also can predict the effect of this
treatment. Gazzaniga et al. [74] determined the expression
profile of multidrug resistance-related proteins (MRPs) of
105 patients with diagnosis of carcinoma, in CTCs isolated
from peripheral blood by CellSearch. Authors were able
to identify a drug-resistance profile of CTCs, which is
predictive of response to chemotherapy, independent of
tumor type and stage of disease with sensitivity 98% and
specificity 100% [74].
Chemosensitivity testing of circulating tumor cells in vitro
To destroy the tumor cells remaining after surgery, adju-
vant chemotherapy is applied to eliminate disseminated
cells. Today, therapy for a particular patient is applied on
the basis of TNM classification and guidelines based
on clinical trials using statistically evaluated longest relapse-
free survival for a given combination of treatment. Un-
fortunately, this does not guarantee whether the chosen
treatment will be successful in individual patients. It is
obvious that the testing of sensitivity to therapeutic agents
directly to the tumor cells of a particular patient would
help to determine appropriate treatment. One way, not
always possible, is a cultivation of tumor cells from the
primary tumor. However, tumors consist of heterogeneous
cell populations [75-77], and it is not clear which cell sub-
population will finally be able to form metastases [78].
The cells released from the tumor tissue in the peripheral
circulation are those that are responsible for a formation
of metastases, and their analysis can help to choose the
best treatment option.
To obtain CTCs, a number of methods may be used,
that can be generally divided into two groups. There are
methods of isolating cells on the basis of phenotypic
properties (surface antigens) which means that it passes
all other cells, however, among which may be even those
which have tumor character. In contrast, there are methods
using all blood cells (red blood cell lysis and one centrifuga-
tion step). This approach avoids preanalytic manipulationwith the samples. Circulating epithelial cells obtained
by these methods could be used to test drug sensitivity,
not only in the metastatic patients but also after primary
tumor resection before adjuvant therapy. Circulating epi-
thelial cells have been shown to respond to therapy in
the same way as the primary tumor [79], and, therefore,
it seems appropriate to test the actual sensitivity of the
residual tumor mass to chemotherapeutic treatment. A
study by Rudiger et al. showed that chemosensitivity
testing of CTC provides real-time information about
the sensitivity of the tumor present in the patient, even
at different times during therapy, and correlates with
treatment success. For isolation of CTC of breast cancer
and ovarian cancer patients, this author used red blood
cell lysis and one centrifugation step and the cell suspen-
sion was subsequently incubated under cell culture condi-
tions with the drugs in question [78]. Gallant et al. in their
work for isolation of CTCs from peripheral blood of CRC
patients used a microfluidic device that enriches CTCs by
size and deformability and showed that isolating a low
number of viable CTCs and maintaining them in a culture
for a few weeks is possible [80].
Drug sensitivity testing on CTCs is a step to personal-
ized cancer treatment strategy, i.e., individualization of
chemotherapy in cancer patients on the base of actual
state of disease. Despite the above discussion, it should
be noted that there remain many questions not fully an-
swered. To what extent it is possible to achieve reproduci-
bility of assessments (in comparison to traditional tumor
markers) in one such question. Of course, there will be
limitations as a result of the kinetics of CTCs in the blood
stream. Finally, it must be mentioned that there are other
techniques which we can use to obtain similar informa-
tion that can be brought by CTCs to oncological patients.
Promising approaches include free circulating nucleic
acids in plasma or serum (CNAPS). This approach uses
the extracellular tumor-derived DNA and/or RNA for
detection of tumor properties [81,82]. Such obtained nucleic
acids can undergo the same molecular genetic analyses as
captured CTCs. On the other hand, such approaches do not
allow morphological analysis of tumor cells.
Conclusions
Before we are able to use real personalized diagnostics
and treatment, it will be necessary to deeply understand
tumor pathogenesis and further phenotype of metastatic
cells and processes they undergo, so that treatment deci-
sions made in individual patients were on the basis of
causal relation of cell phenotype to disease development.
If we suppose that effective treatment of patients with
cancer will be based on targeted therapy directed against
changes of DNA in tumor cells, we must be able to analyze
tumor cells (DNA from tumor cells), moreover, repeatedly
during the disease course. Chemosensitivity testing on
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of the proposed therapy. These are the areas of cancer
management where CTCs are most useful and promising.
The main benefit for the patient is that CTC assessment
is a noninvasive and repeatable tool for individualization
of treatment. It should help not only in primary setting of
the treatment but also in verification of previous treat-
ment decisions and adjustment of treatment according
to current changes.
CTC analysis could be a part of integrative medical ap-
proach of the multimodal diagnostics, disease-specific bio-
marker patterns, individual patient profiles, and treatments
tailored to the person [83] which are the objectives of
PPPM.
Use of the diagnostic potential of CTCs for cancer pa-
tient treatment requires the philosophy and innovative
paradigm as published in the EPMA White Paper [84].
Endnotes
aThe study is coordinated by European Organisation
for Research and Treatment of Cancer, Network of Core
Institutions, and the results will be available in 2015.
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